Led by Intelligence Analysts Deepashri Varadharajan and Ja Lee
From bottlenecks in the enrollment process to rudimentary data collection methods, the $65B clinical trials market needs a makeover.
Current practices in clinical trials have severely delayed the process of promising drugs entering the market. The process begs for disruption, and big pharma companies are recognizing this. For instance, Roche recently acquired healthcare AI company Flatiron for a whooping $1.9B.
In this briefing, we combine CB Insights data with first-hand experience of working at a clinical research site to map a patient’s journey through this process. We explore the use of patient-generated data and the promise and limitations of artificial intelligence.
- What current process for patient recruitment & enrollment looks like and how AI can reduce time and capital involved
- The cost of failed trials for big pharma
- Current methods of medication adherence & protocol compliance in clinical trials and the potential use cases of AI here
- How Apple is disrupting clinical studies
Deepashri Varadharajan received her undergraduate degree in engineering at Vellore Institute of Technology in India. She later studied journalism, and received a degree from the Columbia University Graduate School of Journalism.
Before CB Insights, Deepashri worked for organizations including Al Jazeera America, Deccan Herald, and interned at Siemens India.
Ja Lee is an intelligence analyst at CB Insights, where she produces data-driven analysis and research reports on trends in biotechnology and medical devices.
Prior to joining CB Insights, Ja worked with oncology and neurology clinical trials at Children's National Medical Center. She is a graduate of the University of North Carolina at Chapel Hill with majors in biology and Spanish. She received her Master's degree in physiology from North Carolina State University.